News & Views

First patient dosed in Phase 1 Trial

Iksuda announces first patient dosed in Phase 1 trial of IKS014

13 October 2020

Iksuda enters license agreement with University of Goettingen

Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates

Discover more

16 April 2020

LCB and Iksuda Enter into a Multi-Target Research Collaboration

LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

Discover more

Sign up for more news

Thank you